Compare Adaptive Biotechnologies Corp (ADPT) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Tyson Foods, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Tyson Foods, Inc. trades at $58.4 (market cap $20.71B). The key difference: Tyson Foods, Inc. is far larger — about 6.2× Adaptive Biotechnologies Corp's market cap, and Tyson Foods, Inc. pays a 3.47% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | TSN | |
|---|---|---|
Market Cap | $3.33B | $20.71B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $68.75 |
52-Week Low | $10.24 | $50.72 |
Enterprise Value | $3.19B | $28.30B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Tyson Foods (TSN) trades at $58.82, down 0.12% on the day, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results pending. Revenue for 2025 was $54.44 billion, with a net income margin of 0.81%. Recent news highlights innovation in prepared foods and new product launches, while analyst consensus is a Buy with a $69.75 price target.
The outlook for TSN is cautiously optimistic, supported by analyst bullishness and strategic growth in value-added products. Key opportunities include strong free cash flow guidance and debt reduction. Risks involve volatile cattle prices, inflationary pressures, and competitive market dynamics. The stock presents a potential upside from current levels, contingent on execution of long-term growth strategies and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
